Literature DB >> 8018656

Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells.

J A Rimarachin1, J A Jacobson, P Szabo, J Maclouf, C Creminon, B B Weksler.   

Abstract

Activation of the gene for inducible cyclooxygenase (cyclooxygenase-2 [Cox-2], prostaglandin endoperoxide synthase) is an early response to injury in vascular smooth muscle cells. We used in vitro and in vivo models to demonstrate that activation of quiescent smooth muscle cells by mitogens leads to a rapid, short-term rise in mRNA for Cox-2, followed by synthesis of new Cox-2 enzyme protein and a marked increase in prostaglandin production that depends on new enzyme synthesis. Moreover, the Cox-2 mRNA response observed in smooth muscle cells differs in both time and degree, depending on the particular mitogenic stimulus. Serum, platelet-derived growth factor, epidermal growth factor, and thrombin are strong inducers of Cox-2 mRNA, whereas acidic and basic fibroblast growth factors and interleukin-1 alpha are weak inducers. In contrast to the transient activation of Cox-2 in vitro after introduction of a mitogenic stimulus, the Cox-2 response after in vivo vascular injury extends over many days and may represent protracted cellular activation. During induction of Cox-2 message and protein, expression of constitutive cyclooxygenase (Cox-1) remains unchanged, however. These data suggest a pathophysiological role for Cox-2 in the early modulation of vascular responses to injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018656     DOI: 10.1161/01.atv.14.7.1021

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  19 in total

1.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 2.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

3.  Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms.

Authors:  Matthew R Alexander; Meera Murgai; Christopher W Moehle; Gary K Owens
Journal:  Physiol Genomics       Date:  2012-02-07       Impact factor: 3.107

4.  The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets.

Authors:  K E Bornfeldt; J S Campbell; H Koyama; G M Argast; C C Leslie; E W Raines; E G Krebs; R Ross
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

5.  Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.

Authors:  D Praticò; C Tillmann; Z B Zhang; H Li; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

6.  Regulatory role of prostaglandin E2 in induction of cyclo-oxygenase-2 by a thromboxane A2 analogue (U46619) and basic fibroblast growth factor in porcine aortic smooth-muscle cells.

Authors:  S Karim; E Berrou; S Lévy-Toledano; M Bryckaert; J MacLouf
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

Review 7.  Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.

Authors:  J A Mitchell; T D Warner
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

8.  Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TNFalpha, LPS and M-CSF in human monocytes and macrophages.

Authors:  Yan J Jiang; Biao Lu; Patrick C Choy; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

Review 9.  Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment.

Authors:  Michel A Pontari
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.